Human Hepatitis B Immunoglobulin

Products

Information

The manufacturing process for human hepatitis B immunoglobulin contains a step of low pH incubation for viral inactivation. It contains a suitable amount of glycine as stabilizer, but does not contain any antiseptic or antibiotic. Indications: -Post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to HBsAg-positive or suspected HBsAg-positive material, for example, by needle, oral ingestion or sexual exposure. -For prophylaxis in infants born to HBsAg-positive mothers. Mainly designated for prophylaxis of hepatitis B and suitable for use in Liver transplantation Strength: 400IU/vial (4ml) ,200IU/vial (2ml),100 IU/vial(1ml) -Post-exposure prophylaxis in persons who did not receive prior vaccinations, or whose prior vaccination regimen is incomplete, or when hepatitis B antibody levels are inadequate (<10 IU/L).
Distribution Areas
OceaniaNorth America (USA, Canada)AfricaMiddle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied From
China
All categories
Biopharmaceutical ProductsFinished Dosage FormsBiopharmaceuticals (general category)ImmunologyBiopharmaceutical ServicesProductsServices
Main Categories
Biopharmaceutical ProductsFinished Dosage FormsBiopharmaceutical Services

Log in

See all the content and easy-to-use features by logging in or registering!